The S100PBP antibody targets S100P-binding protein (S100PBP), a protein implicated in cellular processes mediated by the S100 family, which regulates calcium signaling, cell proliferation, and differentiation. S100PBP, also known as CacyBP/SIP, interacts with S100P and other S100 proteins, playing roles in tumorigenesis, metastasis, and inflammatory responses. Initially identified for its binding to S100P, it functions as a scaffold protein, modulating pathways like β-catenin degradation and ERK signaling. Overexpression of S100PBP has been linked to cancers, including gastric, pancreatic, and colorectal cancers, where it promotes cell invasion and chemoresistance. Antibodies against S100PBP are vital tools for studying its expression patterns, subcellular localization (cytoplasmic/nuclear), and interactions in disease models. They enable detection via Western blotting, immunohistochemistry, or immunofluorescence, aiding research into its dual roles as a tumor suppressor or promoter, depending on context. These antibodies also help explore therapeutic strategies targeting S100PBP-associated pathways, particularly in malignancies with dysregulated S100 signaling. Commercial S100PBP antibodies are typically validated for specificity across human and rodent homologs, supporting translational studies in cancer biology and molecular diagnostics.